Antidepressant Suicidality Class Risk Will Be Reviewed By Advisory Committees

FDA releases analysis of pediatric suicidality data for joint meeting of Psychopharmacologic Drugs and Pediatric Advisory Committees. The analysis could result in label changes for antidepressants, FDA Talk Paper says.